9 December, 2025
Our CEO Invited to Speak at the University of Strasbourg’s Faculty of Pharmacy
Last week, on December 5th, our CEO Sacha MIJAILOVIC was invited once again to deliver a two-hour presentation at the Master 2 program at the University of Strasbourg’s Faculty of Pharmacy.
This invitation follows a first successful session earlier this year, in January 2025, and reflects the strong collaboration between our company and the academic community.
30 September, 2025
AI in Compliance: What ISO 42001 and EudraLex Annex 22 Mean for Life Sciences
As Artificial Intelligence (AI) moves from experimental use to operational reality in life sciences, regulatory frameworks are catching up. Two major documents are now leading the way in shaping responsible, auditable AI use in both regulated and non-regulated environments:
3 September, 2025
Turning Deviations and CAPA Into Opportunities for Improvement
In the life sciences sector, quality is not just a regulatory requirement, it is the foundation of trust. Every deviation, non-conformity, or ineffective CAPA plan has the potential to create ripple effects: reputational damage, recurring quality issues, operational inefficiencies, data integrity concerns, or even regulatory findings such as FDA 483s.
2 July, 2025
Our new solution for our Medical Devices clients: V&V Strategy Assessment
At GXP CONSULTING, we’re excited to introduce a new service tailored to one of the critical stages of medical device development: Verification & Validation (V&V).
